Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer, Renal Cell Carcinoma

In brief

This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. This research will advance scientific knowledge by studying the safety of a preoperative dose of ketorolac prior to major surgical resection, which needs to be assessed prior to proceeding with a larger phase II study designed to evaluate traditional efficacy endpoints such as recurrence and overall survival.

Key facts

Study ID

NCT04495894

Run by

Emory University

People needed

68

Starts

2020-08-24

Expected to finish

2024-02-01

Last updated by the study team

2025-03-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathology-proven or suspected stage 1 or 2 NSCLC and Stage 3 tumor stage 3, node stage 0 (T3N0) RCC, that require surgical resection as the treatment of choice
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Ability to understand and the willingness to sign an informed written consent

You may not qualify if…

• Individuals with pure lung ground-glass opacity (GGO) lesions or mixed GGO with <50% solid component
• Patients undergoing pneumonectomy
• History of cancer in the 3 years prior to surgery (except for basal-cell carcinoma of the skin or cervical neoplasia).
• Contraindication for NSAIDs, including peptic ulcer disease, preoperative chronic kidney disease with estimated glomerular filtration rate (eGFR) <45, allergies or intolerance to NSAIDs, coagulation disorder, or age > 80 years
• Having taken an NSAID within 5 days prior to surgery
• Immunocompromised status
• Refusal or inability to understand the protocol and consent form or to receive follow-up in line with the recommendations
• Preoperative hemoglobin < 9.0

Where it is running

• Emory University Hospital Midtown — Atlanta, Georgia, United States
• Emory Clinic — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Winship Cancer Institute — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.